JNJ•benzinga•
Johnson & Johnson Sues Samsung Bioepis Over Alleged Biosimilar Agreement Breach For Its Flagship Psoriasis Drug
Summary
Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® biosimilar, potentially harming market competition.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 26, 2025 by benzinga